BridgeBio Pharma, Inc.

NasdaqGS:BBIO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 8.52 B

Share Price

USD 44.86

Avg Daily Volume

2,917,960

Change (1 day)

-0.58%

Change (1 year)

78.02%

Change (YTD)

63.48%

BridgeBio Pharma, Inc. Operating Income for the Trailing 12 Months (TTM) ending March 31, 2025: USD -697.69 M

BridgeBio Pharma, Inc. Operating Income is USD -697.69 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 46.12% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

BridgeBio Pharma, Inc. Operating Income for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -477.46 M, a 35.89% change year over year.
BridgeBio Pharma, Inc. Operating Income for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -351.35 M, a -37.27% change year over year.
BridgeBio Pharma, Inc. Operating Income for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -560.14 M, a 3.83% change year over year.
BridgeBio Pharma, Inc. Operating Income for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -539.50 M, a 76.94% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGS: BBIO

BridgeBio Pharma, Inc.

CEO	Dr. Neil Kumar Ph.D.
IPO Date	June 27, 2019
Location	United States
Headquarters	421 Kipling Street
Employees	725
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.